Danielle Bucco

Articles

Acalabrutinib Among Exciting Options Emerging in CLL

November 14th 2017

Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.

Efforts Continue to Expand Immunotherapy in CRC

November 13th 2017

Johanna Bendell, MD, discusses the current and emerging treatment landscape of immunotherapy for patients with CRC.

Acquired Mutations Alter Epigenetic Identity in Prostate Cancer

November 8th 2017

Mathieu Lupien, MD, discusses this analysis of the influence of mutations on the epigenetics of prostate cancer.

Expert Sheds Light on Prostate Cancer Screening Trial

November 8th 2017

E. David Crawford, MD, discusses the controversy surrounding the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, as well as the role of prostate-specific antigen testing for men with prostate cancer.

Optimal Combinations, Sequences Being Explored in Multiple Myeloma

November 7th 2017

Adam Waxman, MD, discusses emerging regimens for patients with multiple myeloma.

Triplet Regimens, Maintenance Therapy New Standards for Multiple Myeloma

November 3rd 2017

Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.

BRAF/MEK Combinations Continue to Revolutionize Melanoma Landscape

November 1st 2017

Michael A. Postow, MD, discusses the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

Neoadjuvant Treatment Evolving in HER2-Positive Breast Cancer

October 31st 2017

Elizabeth A. Mittendorf, MD, PhD, discusses the evolving neoadjuvant treatment landscape and other developments in the field of HER2-postive breast cancer.

Immunotherapy, New Targeted Approaches Explored in Thyroid Cancer

October 30th 2017

Gregory Daniels, MD, PhD, discusses the current treatment landscape of thyroid cancer and the development of immunotherapy for patients with this disease.

Emerging Treatments Show Promise in Myelofibrosis

October 27th 2017

Alice Mims, MD, provides updates on the field of myeloproliferative neoplasms, with a focus on myelofibrosis.

Role of Immunotherapy Expanding in Head and Neck Cancer

October 25th 2017

Ezra Cohen, MD, discusses the role of immunotherapy, the potential of entrectinib, and the importance of multidisciplinary teams for the treatment of patients with head and neck cancer.

Hamilton Highlights Progress in HER2-Positive Breast Cancer

October 25th 2017

Erika P. Hamilton, MD, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Durvalumab Has Emerging Role in Head and Neck Cancer

October 24th 2017

Daniel Zandberg, MD, discusses results from the HAWK study as well as current combination approaches for patients with head and neck cancer.

Expert Discusses Immunotherapy Across Gynecologic Malignancies

October 24th 2017

Dmitriy Zamarin, MD, PhD, discusses the role of immunotherapy for patients with gynecologic malignancies.

Nivolumab/Ipilimumab Combo Active for Melanoma Brain Mets

October 21st 2017

The combination of nivolumab and ipilimumab showed an intracranial response rate of 46% for asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

Novel Combinations Mark Next Step for Melanoma

October 20th 2017

Immunotherapy has led a transformation for melanoma care but combinations of anti–PD-1 and CTLA-4 agents are toxic and biomarkers are not available to help personalized treatment, calling for further research into less toxic and more effective options.

Immunotherapy Infuses New Hope Into Merkel Cell Carcinoma Care

October 20th 2017

While chemotherapy has historically been used to treat patients with Merkel cell carcinoma, immunotherapy advances have infused new hope into the treatment landscape.

Expert Covers Burgeoning Advancements in Follicular Lymphoma and MCL

October 18th 2017

Narendranath Epperla, MD, discusses the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Intralesional Combinations Pave the Way for Melanoma Treatment

October 18th 2017

The use of intralesional therapies in combination with checkpoint inhibitors has shown to be an improvement to monotherapy and combinations with immunotherapy in melanoma.

Expert Discusses Ongoing Advances in CLL

October 17th 2017

Farrukh Awan, MD, discusses novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.